Cytek Biosciences FY Conference Summary Company Overview - **Company**: Cytek Biosciences (NasdaqGS:CTKB) - **Industry**: Cell analysis, specifically focusing on flow cytometers - **Growth Recognition**: Named one of the leading growth companies in the U.S. by Time Magazine [2][4] Key Financial Metrics - **Revenue**: $201.5 million in FY 2025, representing a 1% growth year-over-year despite a 4% decline in the overall flow cytometry market [4][11] - **Cash Position**: $261.5 million since going public, with positive cash flow generation [4][5] - **Market Share**: Cytek outperformed the market by gaining market share during a period of overall market decline [4][11] Product Launches and Innovations - **New Products**: - **Aurora Evo**: Launched in 2025, received positive feedback and is now a dominant product in sales [21][17] - **Muse Macro**: Awarded the BioTech Breakthrough Award of 2025 [2] - **Product Portfolio**: Broad range of instruments and reagents, including high-end products like Aurora Evo and CellSorter, and mid-level applications like Northern Lights and Muse Micro [12][17] Market Dynamics - **Flow Cytometry Market**: Estimated to grow from $5 billion to $9.2 billion by 2032, with a CAGR of 8.8% [11] - **Geographic Revenue Distribution**: - 47% from the U.S. - 28% from APAC - 25% from the rest of the world [7] - **Regional Growth**: APAC is expected to grow faster than the U.S., with government incentives driving investment in China [33] Customer Segments - **Revenue by Industry**: - 58% from pharma, biotech, and CROs - 42% from academic and government sectors [8] - **Customer Base**: Approximately 3,000 unique institutions and over 24,000 users on Cytek Cloud [3][14] Future Growth Drivers - **Service and Reagents**: Expected to grow at rates consistent with 2025, with a target of increasing recurring revenue from 34% to 40% over the next few years [17][24] - **Clinical Applications**: Expansion in Europe and China, with partnerships to drive clinical adoption [15][19] - **Installed Base**: Growing installed base is expected to generate consistent revenue growth [40] Challenges and Market Sentiment - **Funding Concerns**: Academic and government markets faced funding cuts, but sentiment has improved compared to the previous year [26][29] - **Pharma Spending**: While there were contractions in 2025, a return to growth is anticipated in 2026 as funding is reevaluated [28][30] Conclusion - **Strategic Positioning**: Cytek is well-positioned to capitalize on market growth through innovation, geographic expansion, and a diversified customer base. The company continues to outperform the market and is expected to maintain its growth trajectory in the coming years [10][39]

Financial Data and Key Metrics Changes - Fourth quarter revenue for 2025 reached $62.1 million, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history [4][14] - Full year revenue for 2025 was $201.5 million, a 1% increase compared to 2024, with a notable turnaround in the second half of the year where revenue grew by 5% compared to the second half of 2024 [6][24] - GAAP gross profit for Q4 was $32.9 million, a 2% decline from $33.7 million in Q4 2024, with a gross margin of 53% compared to 59% in the prior year [17][18] - Net loss for Q4 was $44.1 million, compared to net income of $9.6 million in the prior year quarter, primarily due to a $38.1 million valuation allowance against deferred tax assets [20][22] Business Line Data and Key Metrics Changes - Instrument revenue grew 22% in 2025 compared to the prior year, with a 26% growth in Q4 [8] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year 2025, driven by improvements in delivery times and a large catalog of reagents [10][16] - Service revenue grew 25% in Q4 year-over-year, supported by an expanding installed base and active usage of systems [16] Market Data and Key Metrics Changes - In the U.S., total revenue grew by 5% in Q4, driven by double-digit growth in service revenue, while EMEA grew 21% due to strong demand from academic and government customers [17] - APAC, including China, experienced a 15% growth in Q4, driven by increases in instruments, service, and reagents [17] Company Strategy and Development Direction - The company aims to reinforce its market leadership in next-gen cell analysis solutions by focusing on core strategic pillars: instrument, application, bioinformatics, and clinical [7] - The company plans to continue expanding its global footprint and enhancing its operational capabilities, including a new manufacturing facility in Singapore [11] Management's Comments on Operating Environment and Future Outlook - Management noted a stabilization in the market environment, particularly in academic and government spending, which contributed to the revenue growth in Q4 [42] - The company anticipates continued growth in 2026, with a revenue outlook of $205 million to $212 million, reflecting improved market conditions in EMEA and the U.S. [31][32] Other Important Information - The company reported a free cash flow of -$0.2 million in Q4, with total cash and marketable securities at $261.5 million as of December 31, 2025 [24][30] - The company repurchased approximately $15.1 million of its stock during 2025, reflecting a commitment to returning value to shareholders [30] Q&A Session Summary Question: What drove the end-of-year growth acceleration? - Management indicated that the growth was driven by a normalization in academic and government spending, along with some catch-up disbursements from the NIH [42][43] Question: What was the mix in 2025 between new customer acquisitions versus existing customers expanding their capacity? - Management noted that the growth was a combination of both new customer acquisitions and existing customers purchasing additional systems [50] Question: How is the company thinking about commercial investments in 2026? - The company plans to continue investing in its sales teams and reagent sales force to drive future revenue growth [52][53]

Summary of Cytek Biosciences FY Conference Call Company Overview - **Company**: Cytek Biosciences (NasdaqGS:CTKB) - **Industry**: Life Science Tools and Diagnostics - **Focus**: Flow cytometry technology and related services Key Points Market Performance and Growth - **Revenue Growth**: 85% of the business is experiencing double-digit growth, particularly in service, reagents, and instrument sectors, excluding Europe [2][4] - **Geographical Insights**: - **Asia-Pacific**: Expected to continue strong growth [2] - **US Market**: Stabilizing with positive revenue growth in Q3 [2] - **Europe**: Facing contraction due to previous market conditions, but signs of recovery are anticipated [2][20] Technology and Competitive Advantage - **Innovative Approach**: Cytek leverages advancements from the telecommunications sector to enhance flow cytometry, marking a significant shift in the industry [3][4] - **Product Leadership**: Cytek has deployed over 3,000 instruments, establishing itself as a leader in full spectral flow cytometry technology [4][31] - **Aurora Evo Instrument**: - Features include nanoparticle detection, automated shutdown, and remote operation, designed to meet pharmaceutical needs [12][13] - High throughput and productivity enhancements are expected to drive adoption and revenue growth [14][10] Funding Landscape and Market Dynamics - **NIH Funding**: Academic customers are diversifying funding sources; only one-third of sales are directly linked to NIH funding [6][5] - **Pharma Market Trends**: - Instrument sales in Europe saw a pause after significant growth in 2023 and 2024, while the US market showed a 12% growth in biopharma [9][10] - Cytek's technology is positioned well to capitalize on the positive secular trends in the pharma sector [9] Regional Challenges and Strategies - **EMEA Market**: - Facing challenges due to government spending cuts and a slowdown in instrument sales [19][20] - Reagent growth in EMEA is strong, indicating a positive trend despite instrument sales challenges [23] - Cytek is investing in service and sales networks in EMEA to strengthen its market position [24] Revenue Streams and Future Outlook - **Consumables and Services**: - Revenue per instrument remains stable, with service revenue growing alongside the installed base [26] - Reagent growth is robust, with a year-over-year increase close to 20%, indicating strong market share gains [28][15] - **Future Opportunities**: - Potential for $200 million in reagent revenue from the existing installed base [15] - Continued investment in marketing and sales for reagents to drive future growth [27] Competitive Landscape - **Market Positioning**: Cytek maintains a strong competitive edge through a comprehensive product and service offering, including the Cytek Cloud and Panel Builder [33] - **Emerging Markets**: The Guava Muse platform targets entry-level users and is designed for convenience and mobility, expanding Cytek's reach in cost-sensitive markets [34] Conclusion Cytek Biosciences is positioned for continued growth in the life sciences tools market, driven by innovative technology, strong performance in key regions, and a focus on expanding its consumables and services. The company is navigating challenges in the EMEA market while capitalizing on opportunities in Asia-Pacific and the US.

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 reached $52.3 million, a year-over-year increase of 2% compared to Q3 2024, driven by strong growth in Asia-Pacific and recurring revenue from services and reagents [6][17][19] - Product revenue, which includes instruments and reagents, decreased by 4% year-over-year, primarily due to a 26% decline in EMEA, offset by a 19% growth in APAC [17][19] - Net loss for Q3 was $5.5 million, compared to a net income of $0.9 million in the prior year quarter, driven by higher operating losses and lower net other income [23][24] Business Line Data and Key Metrics Changes - Instrument revenue to pharma and biotech customers grew 12% worldwide, with a 10% increase in the U.S., driven by the launch of the Aurora EVOS instrument [8][17] - Service revenue grew 19% year-over-year, supported by an expanding installed base and strong utilization of products [19][24] - Reagent revenue achieved its highest-ever quarterly revenue in Q3, representing a 21% growth over the prior year quarter [18][19] Market Data and Key Metrics Changes - U.S. revenue grew 12% in Q3 compared to the prior year, driven by service revenue growth, while EMEA experienced a 28% decline due to lower instrument revenue [19][24] - APAC, including China, saw a 25% increase in revenue, driven by growth in instruments, service, and reagents [19][24] - The Rest of World regions, including Canada and Latin America, achieved double-digit overall revenue growth compared to the third quarter of last year [8] Company Strategy and Development Direction - The company is focused on expanding its global footprint and enhancing its product offerings, including the introduction of the Aurora EVOS analyzer, which has received a strong reception [11][12] - Cytek is committed to driving growth in its reagent product line and has expanded its European headquarters to improve operational efficiency [12][13] - The company aims to leverage its Cytek Cloud platform to enhance customer experience and drive growth in its reagent and service businesses [14][15] Management's Comments on Operating Environment and Future Outlook - Management noted that the U.S. market is showing signs of stabilization, while EMEA remains challenged due to shifts in public spending priorities [25][40] - The company expects continued strong growth in instruments in APAC and stabilization in U.S. instruments, with a reaffirmed full-year 2025 revenue outlook of $196 million to $205 million [24][25] - Management believes that the clinical market represents an attractive business opportunity, particularly with the approval of Cytek's Northern Lights CLC system for clinical use in the EU [16] Other Important Information - The company reported a GAAP gross profit of $27.6 million, a 5% decrease from Q3 2024, with a gross margin of 53% [19][20] - Operating expenses increased by 10% year-over-year, primarily due to higher general and administrative expenses related to legal costs [20][22] - Free cash flow was slightly negative at minus $0.3 million, reducing total cash and marketable securities to $261.7 million [24] Q&A Session Summary Question: Differences in the Aurora EVO product compared to others in the market - Management highlighted that the Aurora EVO includes features such as higher throughput and small particle detection, tailored for pharma customers [30] Question: Insights on double-digit growth in CROs and implications for biopharma - Management clarified that instrument revenue to the aggregate group of pharma, biotech, and CROs grew 12% worldwide, indicating strong demand [32] Question: Quality of customer conversations and spending appetite for next year - Management noted strong growth in Asia-Pacific and stable trends in the U.S., with expectations for continued growth in biopharma spending [38][39] Question: Key assumptions behind the 2025 outlook - Management expects typical seasonal improvement in Q4 driven by budget flush from biopharma customers [41][50] Question: Trends in U.S. academic and government demand - Management indicated that demand continues to be under pressure, with no significant changes expected [42] Question: Initiatives to increase reagent capture rate - Management mentioned improvements in operational efficiency, logistics, and the expansion of facilities to enhance reagent business [43][44] Question: Capital deployment and appetite for share buybacks or acquisitions - Management aims to balance share repurchase and M&A opportunities, with a focus on maintaining a strong balance sheet [53][54]

Financial Data and Key Metrics Changes - Full year revenue in 2024 grew 4% over 2023, reaching $200.5 million, driven by strong growth in service revenue and double-digit growth in international markets outside of the U.S. [12] - Adjusted EBITDA for 2024 was $22.4 million, a gain of more than 77% compared to $12.6 million in 2023 [15][54] - Fourth quarter revenue was $57.5 million, essentially flat compared to Q4 2023 after adjusting for the strong appreciation of the U.S. dollar [16][36] - GAAP net income for Q4 was $9.6 million, including a $2.6 million nonrecurring benefit [45] Business Line Data and Key Metrics Changes - Service revenue grew 8% year-over-year in Q4, mainly due to the growth in the total installed base of instruments [16][38] - Product revenue decreased 3% versus Q4 2023 but increased 14% sequentially versus Q3 2024 [37] - Northern Lights CLC unit placements grew by 15% in 2024 compared to 2023, achieving the highest placement growth rate across the product portfolio [33] Market Data and Key Metrics Changes - Total U.S. revenue declined 10% compared to Q4 last year, driven by lower instrument sales [39] - Asia Pacific revenue grew 21%, driven by strong growth in China [39] - Other international markets, primarily Canada and Latin America, also saw strong growth, with revenue reaching $5.3 million in Q4 compared to $1.9 million in the prior year quarter [39] Company Strategy and Development Direction - The company is focused on driving sustainable growth and profitability through technological leadership and excellent user support [13][34] - The recent acquisition of Luminex has diversified the instrument portfolio and enhanced technical capabilities [25][27] - The company aims to solidify its position as a market leader in next-gen cell analysis solutions [34] Management's Comments on Operating Environment and Future Outlook - Management expressed a conservative stance on the China market due to a dynamic environment but noted an uptick in orders related to the China stimulus program [16] - The company expects solid growth in service business and good momentum in instrument sales in APAC, despite softer market conditions in the U.S. and EMEA [59][60] - Full year revenue guidance for 2025 is projected to be in the range of $204 million to $212 million, representing overall growth of 2% to 6% over 2024 [60] Other Important Information - The company repurchased approximately 4 million shares for a total cost of approximately $21.6 million in 2024 [56][57] - Cytek Cloud user base grew by more than 160% in 2024, reaching over 16,000 users [30][124] Q&A Session Summary Question: Can you talk about the 8.5% instrument growth and the mix? - Management noted good growth in Northern Lights and expects that momentum to carry forward, but did not provide specific guidance on product categories [66][70] Question: Can you summarize the impact of recent tariffs and export controls? - Management indicated that the company has a flexible global manufacturing system to mitigate potential impacts from tariffs and export controls [76][80] Question: What is the exposure to NIH funding and its impact? - The company estimated that around 5% of total revenue was funded by NIH grants, with a potential 8% reduction in funding [90][92] Question: What are the expectations for service revenue growth in 2025? - Management expects to continue solid growth in service revenues, driven by the growing installed base [114] Question: Is the company open to additional M&A? - Management confirmed openness to M&A, focusing on businesses in existing or adjacent markets that can contribute positive EBITDA within a year [120][121]

Financial Data and Key Metrics Changes - Full year revenue in 2024 grew 4% over 2023, reaching $200.5 million, driven by strong growth in service revenue and double-digit growth in international markets outside of the U.S. [12] - Adjusted EBITDA for 2024 was $22.4 million, a gain of more than 77% compared to $12.6 million in 2023 [15][54] - Fourth quarter revenue was $57.5 million, essentially flat compared to Q4 2023 after adjusting for the strong appreciation of the U.S. dollar [16][36] - GAAP gross profit for Q4 2024 was $33.7 million, an increase of 2% compared to Q4 2023 [40] Business Line Data and Key Metrics Changes - Service revenue grew 8% year-over-year in Q4 2024, mainly due to the growth in the total installed base of instruments [16][38] - Product revenue decreased 3% versus Q4 2023 but increased 14% sequentially versus Q3 2024 [37] - Northern Lights CLC unit placements grew by 15% in 2024 compared to 2023, achieving the highest placement growth rate across the product portfolio [33] Market Data and Key Metrics Changes - Total U.S. revenue declined 10% compared to Q4 2023, driven by lower instrument sales [39] - Asia Pacific revenue grew 21%, driven by strong growth in China [39] - Other international markets, primarily Canada and Latin America, also saw strong growth, with revenue reaching $5.3 million in Q4 2024 compared to $1.9 million in the prior year quarter [39] Company Strategy and Development Direction - The company aims to solidify its position as a market leader in next-gen cell analysis solutions through key growth pillars: Instruments, Applications, Bioinformatics, and Clinical [18] - The recent acquisition of Luminex has diversified the instrument portfolio and enhanced technical capabilities [25] - The company opened a new manufacturing facility in Singapore to increase capacity and enhance global supply chain flexibility [28] Management's Comments on Operating Environment and Future Outlook - Management expressed a conservative stance on the China market due to a dynamic environment but noted an uptick in orders related to the China stimulus program [16] - The company expects solid growth in service business and good momentum in instrument sales in APAC, despite softer market conditions in the U.S. and EMEA [59] - Full year revenue guidance for 2025 is projected to be in the range of $204 million to $212 million, representing overall growth of 2% to 6% over 2024 [60] Other Important Information - The company repurchased approximately 4 million shares for a total cost of approximately $21.6 million during 2024 [56] - Cytek Cloud user base grew to over 16,000, expanding by more than 160% from the start of 2024 [30] Q&A Session Summary Question: Can you talk about the 8.5% instrument growth and the mix? - Management noted good growth in Northern Lights and expects that momentum to carry forward, but did not provide specific guidance on product categories [66][70] Question: Can you summarize the impact of recent tariffs and export controls? - Management indicated that the diversified manufacturing locations provide flexibility to mitigate potential impacts from tariffs [76][80] Question: What is the exposure to NIH funding and its impact? - The company estimated around 5% of total revenue is funded by NIH grants, with a potential 8% reduction in funding [90][92] Question: What are the expectations for service revenue growth in 2025? - Management expects a continuation of the good momentum seen in service revenues in 2024 [114] Question: Is the company open to additional M&A? - Management confirmed openness to M&A, focusing on businesses in existing or adjacent markets that can contribute positive EBITDA within a year [120]